Fever During Anti-integrin Therapy: New Immunodeficiency

Area of Science:

• Gastroenterology
• Immunology
• Infectious Diseases

Background:

• Inflammatory bowel disease (IBD) pathogenesis involves genetic, microbial, and environmental factors, leading to immune dysregulation and impaired intestinal barrier function.
• Current IBD treatments include conventional immunosuppressants and targeted biological agents, but systemic immune suppression increases the risk of opportunistic infections like cytomegalovirus (CMV).

Purpose of the Study:

• To highlight the potential risk of cytomegalovirus (CMV) infection in patients with inflammatory bowel disease (IBD) undergoing treatment with biological agents.
• To emphasize the importance of considering CMV infection in IBD patients presenting with systemic symptoms.

Main Methods:

• Case report of a 33-year-old male with ulcerative colitis and primary sclerosing cholangitis treated with azathioprine and vedolizumab.
• Patient presented with fever, fatigue, and headache; CMV infection was diagnosed via serology.
• Treatment involved intravenous ganciclovir therapy.

Main Results:

• The patient was diagnosed with primary cytomegalovirus (CMV) infection.
• Successful treatment of CMV infection was achieved with intravenous ganciclovir.
• The case underscores the association between immunosuppressive therapy for IBD and CMV infection risk.

Conclusions:

• Vedolizumab, a gut-selective anti-integrin agent for IBD, may have a favorable safety profile, but data are limited.
• IBD patients on immunosuppression are at increased risk for both primary and reactivation CMV infections.
• Clinical vigilance for CMV infection is essential in the management of inflammatory bowel disease.